HomeComparePFE vs NKE

PFE vs NKE: Dividend Comparison 2026

PFE yields 6.20% · NKE yields 3.16%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NKE wins by $1.80M in total portfolio value
10 years
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →
NKE
NKE
● Live price
3.16%
Share price
$51.24
Annual div
$1.62
5Y div CAGR
66.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.85M
Annual income
$1,337,341.87
Full NKE calculator →

Portfolio growth — PFE vs NKE

📍 NKE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPFENKE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PFE + NKE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PFE pays
NKE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
NKE
Annual income on $10K today (after 15% tax)
$268.74/yr
After 10yr DRIP, annual income (after tax)
$1,136,740.59/yr
At 15% tax rate, NKE beats the other by $1,113,611.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PFE + NKE for your $10,000?

PFE: 50%NKE: 50%
100% NKE50/50100% PFE
Portfolio after 10yr
$951.4K
Annual income
$682,276.20/yr
Blended yield
71.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NKE right now

PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
NKE
Analyst Ratings
1
Strong
42
Buy
23
Hold
4
Sell
Consensus: Buy
Price Target
$75.35
+47.1% upside vs current
Range: $62.00 — $110.00
Altman Z
3.8
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PFE buys
0
NKE buys
0
No recent congressional trades found for PFE or NKE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPFENKE
Forward yield6.20%3.16%
Annual dividend / share$1.72$1.62
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.2%66.3%
Portfolio after 10y$51.1K$1.85M
Annual income after 10y$27,210.54$1,337,341.87
Total dividends collected$60.1K$1.78M
Payment frequencyquarterlyquarterly
SectorHealthcareConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$27.50$75.35

Year-by-year: PFE vs NKE ($10,000, DRIP)

YearPFE PortfolioPFE Income/yrNKE PortfolioNKE Income/yrGap
1← crossover$9,161$701.38$11,226$525.77$2.1KNKE
2$8,610$859.79$12,929$917.32$4.3KNKE
3$8,366$1,081.25$15,476$1,642.01$7.1KNKE
4$8,483$1,405.66$19,614$3,054.78$11.1KNKE
5$9,084$1,907.24$27,004$6,017.26$17.9KNKE
6$10,418$2,732.78$41,770$12,875.77$31.4KNKE
7$13,007$4,193.56$75,648$30,954.02$62.6KNKE
8$18,010$7,005.87$168,071$87,127.77$150.1KNKE
9$28,216$12,979.89$480,693$300,856.83$452.5KNKE
10$51,081$27,210.54$1,851,684$1,337,341.87$1.80MNKE

PFE vs NKE: Complete Analysis 2026

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →

NKEConsumer Discretionary

NIKE, Inc., together with its subsidiaries, designs, develops, markets, and sells men's, women's, and kids athletic footwear, apparel, equipment, and accessories worldwide. The company provides athletic and casual footwear, apparel, and accessories under the Jumpman trademark; and casual sneakers, apparel, and accessories under the Converse, Chuck Taylor, All Star, One Star, Star Chevron, and Jack Purcell trademarks. In addition, it sells a line of performance equipment and accessories comprising bags, socks, sport balls, eyewear, timepieces, digital devices, bats, gloves, protective equipment, and other equipment for sports activities under the NIKE brand; and various plastic products to other manufacturers. The company markets apparel with licensed college and professional team, and league logos, as well as sells sports apparel. Additionally, it licenses unaffiliated parties to manufacture and sell apparel, digital devices, and applications and other equipment for sports activities under NIKE-owned trademarks. The company sells its products to footwear stores; sporting goods stores; athletic specialty stores; department stores; skate, tennis, and golf shops; and other retail accounts through NIKE-owned retail stores, digital platforms, independent distributors, licensees, and sales representatives. The company was formerly known as Blue Ribbon Sports, Inc. and changed its name to NIKE, Inc. in 1971. NIKE, Inc. was founded in 1964 and is headquartered in Beaverton, Oregon.

Full NKE Calculator →
📬

Get this PFE vs NKE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PFE vs JNJPFE vs MRKPFE vs ABBVPFE vs BMYPFE vs LLYPFE vs SCHDPFE vs JEPIPFE vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.